XTX Topco Ltd Purchases Shares of 33,004 Organon & Co. (NYSE:OGN)

XTX Topco Ltd acquired a new position in Organon & Co. (NYSE:OGN) during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The fund acquired 33,004 shares of the company’s stock, valued at approximately $683,000.

A number of other hedge funds and other institutional investors have also made changes to their positions in OGN. Mercer Global Advisors Inc. ADV grew its position in Organon & Co. by 1.8% in the second quarter. Mercer Global Advisors Inc. ADV now owns 31,086 shares of the company’s stock worth $674,000 after buying an additional 546 shares during the last quarter. Ballentine Partners LLC grew its holdings in shares of Organon & Co. by 3.0% in the 2nd quarter. Ballentine Partners LLC now owns 19,105 shares of the company’s stock worth $395,000 after acquiring an additional 552 shares during the last quarter. Atomi Financial Group Inc. grew its holdings in shares of Organon & Co. by 1.8% in the 1st quarter. Atomi Financial Group Inc. now owns 32,858 shares of the company’s stock worth $618,000 after acquiring an additional 593 shares during the last quarter. Bill Few Associates Inc. raised its position in shares of Organon & Co. by 5.4% during the second quarter. Bill Few Associates Inc. now owns 12,218 shares of the company’s stock worth $253,000 after purchasing an additional 621 shares during the period. Finally, GAMMA Investing LLC lifted its holdings in shares of Organon & Co. by 19.2% during the second quarter. GAMMA Investing LLC now owns 4,036 shares of the company’s stock valued at $84,000 after purchasing an additional 649 shares during the last quarter. 77.43% of the stock is currently owned by institutional investors.

Organon & Co. Stock Down 3.4 %

NYSE:OGN opened at $19.49 on Monday. The business’s fifty day moving average price is $21.00 and its 200 day moving average price is $20.11. The firm has a market capitalization of $5.01 billion, a price-to-earnings ratio of 4.77, a PEG ratio of 0.89 and a beta of 0.85. The company has a current ratio of 1.64, a quick ratio of 1.17 and a debt-to-equity ratio of 60.05. Organon & Co. has a 1-year low of $10.84 and a 1-year high of $23.10.

Organon & Co. (NYSE:OGN) last posted its quarterly earnings results on Tuesday, August 6th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.08 by $0.04. Organon & Co. had a net margin of 15.76% and a negative return on equity of 840.29%. The business had revenue of $1.61 billion during the quarter, compared to analyst estimates of $1.61 billion. During the same period in the prior year, the firm earned $1.31 earnings per share. The firm’s revenue was down .1% compared to the same quarter last year. On average, sell-side analysts forecast that Organon & Co. will post 4.14 earnings per share for the current fiscal year.

Organon & Co. Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, September 12th. Stockholders of record on Friday, August 16th were issued a dividend of $0.28 per share. This represents a $1.12 annualized dividend and a dividend yield of 5.75%. The ex-dividend date of this dividend was Friday, August 16th. Organon & Co.’s dividend payout ratio is currently 27.38%.

Analysts Set New Price Targets

Separately, JPMorgan Chase & Co. cut Organon & Co. from a “neutral” rating to an “underweight” rating and lifted their price target for the stock from $18.00 to $20.00 in a research note on Friday, September 6th.

Organon & Co. Company Profile

Organon & Co develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage.